Ignite Creation Date:
2024-05-06 @ 8:18 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06336512
Status:
COMPLETED
Last Update Posted:
2024-03-28
First Post:
2024-03-22
Brief Title:
Trimester Sequential Estimation of Serum Zonulin as a Predictor of Gestational Diabetes Mellitus
Sponsor:
Benha University
Organization:
Benha University
Study Overview
Official Title:
Trimester Sequential Estimation of Serum Zonulin Overrides Glucose Homeostasis Biomarkers for Prediction of Gestational Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Gestational diabetes mellitus GDM is the development of glucose intolerance GI during pregnancy in a previously normoglycemic NG woman and associated with insulin resistance IR GDM is the most prevalent metabolic disorder during pregnancy and became a major public health problem for being usually diagnosed and detected after 24 gestational weeks GW while its complications can occur much earlier and this may explain its burden on maternal and fetal welfare Human zonulin is a surrogate marker of intestinal permeability and can be utilized as biomarker for intestinal barrier function Zonulin-mediated increase in intestinal permeability plays a role in the pathogenesis of insulin resistance obesity DM and metabolic syndrome The increasing global prevalence of GDM with its associated risk of poor pregnancy and long-term risks for the mother and the offspring may lead to the production of new generation of diabetics
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None